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Edited by Jesus AvilaAbstract Abnormal phosphorylation of tau protein represents
one of the major candidate pathological mechanisms leading to
Alzheimer’s disease (AD) and related tauopathies. Altered phos-
phorylation status of neuronal tau protein may result from
upregulation of tau-speciﬁc kinases or from inhibition of tau-spe-
ciﬁc phosphatases. Increased expression of the protein inhibitor 1
of protein phosphatase 2A (I1PP2A) could therefore indirectly
regulate the phosphorylation status of tau. As an important step
towards elucidation of the role of I1PP2A in the physiology and
pathology of tau phosphorylation, we developed a novel monoclo-
nal antibody, DC63, which recognizes I1PP2A. Speciﬁcity of the
antibody was examined by mass spectrometry and Western blot.
This analysis supports the conclusion that the antibody does not
recognize any of the other proteins of the 9-member leucine-rich
acidic nuclear phosphoprotein family to which I1PP2A belongs.
Immunoblot detection revealed that the inhibitor I1PP2A is ex-
pressed throughout the brain, including the hippocampus, tempo-
ral cortex, parietal cortex, subcortical nuclei and brain stem.
The cerebellum displayed signiﬁcantly higher levels of expression
of I1PP2A than was seen elsewhere in the brain. Imunohisto-
chemical analysis of normal human brain showed that I1PP2A
is expressed in both neurons and glial cells and that the protein
is preferentially localized to the nucleus. We conclude that the
novel monoclonal antibody DC63 could be successfully employed
as a mass spectrometry-validated molecular probe that may be
used for in vitro and in vivo qualitative and quantitative studies
of physiological and pathological pathways involving I1PP2A.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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It has been shown that microtubule associated protein tau is
abnormally phosphorylated [1] and truncated in Alzheimer’sAbbreviations: AD, Alzheimer’s disease; PP2A, protein phosphatase
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doi:10.1016/j.febslet.2007.01.015disease (AD) [2,3]. The hyperphosphorylation of tau results
from an imbalance of the activities of tau kinases and tau
phosphatases as well as from conformational changes of tau
that inﬂuence its ability to interact with these enzymes [4–8].
Protein phosphatase 2A (PP2A) is the major tau phospha-
tase in the brain [9] and was shown to exhibit reduced activity
in aﬀected areas of brains from AD patients [9–13]. These
observations suggest that downregulation of phosphatase
activity in human brain is involved in the cascade of patholog-
ical events leading to reduced tau function, protein aggrega-
tion, and neuronal degeneration.
In vitro studies identiﬁed a potent inhibitor of PP2A which
was subsequently named inhibitor 1 of PP2A, or I1PP2A
[14,15]. This ﬁnding was extended by in vivo studies that
showed that I1PP2A is over-expressed in AD brains [16,17].
I1PP2A, which is also known as leucine-rich acidic nuclear
protein (LANP), phosphoprotein PP32, PHAP-I, and
mapmodulin, has been implicated in a variety of cellular func-
tions including tumor suppression [18–20], cell-mediated
cytotoxicity [21], signal transduction [22], regulation of micro-
tubule function, and microtubule-based vesicular traﬃcking
[23–25].
The inhibitor I1PP2A is a member of the Anp32 family con-
sisting of 32 evolutionarily conserved proteins and is included
within the superfamily of leucine-rich repeat (LRR) proteins
characterized by the presence of tandem arrays of LRR, a
structural motif implicated in the mediation of protein–protein
interactions. In humans, the closely related family of acidic
leucine rich nuclear phosphoproteins consists of nine highly
conserved members (Anp32A/I1PP2A, ANP32B1, B2, C, D,
E, F, G, H) [26]. The high degree of sequence conservation
could lead to diﬃculties in discriminating amongst diﬀerent
I1 inhibitor family members expressed in human brain. There-
fore the goal of our work was to produce and characterize a
molecular probe – a monoclonal antibody, that would
unequivocally identify the inhibitor I1PP2A in various human
brain regions. To be of greatest utility, such a speciﬁc probe
should meet the following criteria: (a) recognize I1PP2A on
Western blot analysis as a single band of 30 kDa; (b) immuno-
aﬃnity purify I1PP2A as a single molecular species, conﬁrmed
by mass spectrometric analysis; and (c) prove suitable for
immunohistochemical and Western blot analysis of human
brain tissue.blished by Elsevier B.V. All rights reserved.
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DC63. Immunoaﬃnity puriﬁcation and Western blot analysis
demonstrate that the monoclonal antibody DC63 recognizes
a single protein in human brain extract, which was identiﬁed
by mass spectrometry as I1PP2A. To our knowledge this is
the ﬁrst monoclonal antibody conﬁrmed by mass spectrometry
analysis to recognize I1PP2A and to distinguish it from other
members of the highly conserved Anp32 family of proteins.
Using human brain autopsy samples we found that I1PP2A
is expressed in all brain areas tested, including the cerebellum
where expression levels are roughly twice that observed in
other brain regions. Furthermore, we show that I1PP2A is ex-
pressed in the nuclei of both neurons and glial cells. The mono-
clonal antibody DC63 therefore provides an eﬃcient and
highly speciﬁc tool that may be used to elucidate the role of
I1PP2A in pathogenesis of AD and related tauopathies.
2. Materials and methods
2.1. I1PP2A cDNA cloning and production of recombinant I1PP2A
I1PP2A cDNA was isolated from normal human brain by RT-PCR
and veriﬁed byDNA sequencing. The cDNAwas cloned into a prokary-
otic expression vector pET17b and recombinant I1PP2A was produced
in Escherichia coli. The protein was puriﬁed by a combination of anion
exchange and size-exclusion chromatography essentially as described
previously for some of the recombinant truncated tau proteins [27].
2.2. Generation of the DC63 antibody
Monoclonal antibody DC63 was generated by immunizing BALB/c
mice with puriﬁed recombinant I1PP2A according to the protocol de-
scribed previously [28].
2.3. Immunoaﬃnity batch puriﬁcation of inhibitor I1 from human brain
tissue
DC63 antibody was covalently attached to Tosylactivated Dynabe-
ads M280 (Dynal) according to manufacturer’s instructions. One hun-
dred and forty microliters of the beads (50% suspension) were
incubated with human non-AD brain extract (3 mg) in phosphate-buf-
fered saline (PBS, 10 mM Na-phosphate pH 7.4, 150 mM NaCl) sup-
plemented with 0.17% Tween 20, 0.17% NP-40 and a cocktail of
protease inhibitors (Complete without EDTA, Roche Diagnostics,
Switzerland) at 4 C for 3 h. The beads were then washed three times
for 5 min with PBS containing 0.2%Tween 20. The control antibody
DC51, raised against a coat protein of rabies virus (Dr. Kontsekova,
Institute of Neuroimmunology SAS, Bratislava, Slovakia), was used
as a negative control for mock puriﬁcations under the same conditions
as described above for DC63. The washed DC63- and DC51-coupled
Dynabeads were suspended in 30 ll of 1 · SDS sample loading buﬀer
[29] and the puriﬁcation eﬃciency was analyzed by immunoblotting
with the DC63 antibody. The immunoaﬃnity DC63 puriﬁed protein
was subjected to mass spectrometric analysis.2.4. Mass spectrometric analysis
The appropriate region of polyacrylamide gel piece containing
DC63-immunoaﬃnity puriﬁed I1PP2A protein was crushed into 1–
2 mm pieces, washed with 100 mM NH4HCO3, dehydrated with aceto-
nitrile (Merck) and dried. Intra-protein disulﬁde bonds were reduced
by incubation with 10 mM dithiothreitol (Roth, Germany) in
100 mM NH4HCO3 for 1 h at 60 C and then blocked by alkylation
with 55 mM iodoacetamide (Sigma) in 100 mM NH4HCO3 for
45 min at room temperature in the dark. After washing with
100 mM NH4HCO3 and dehydration with acetonitrile, the gel pieces
were rehydrated with a solution containing 0.0125 lg/ll of Trypsin
sequencing grade (Promega) in 50 mM NH4HCO3 and then incubated
at 37 C overnight. The buﬀer was collected and the gel pieces were fur-
ther extracted once with 20 ll of 50 mM NH4HCO3 and twice with
20 ll of 5% formic acid.
Forty microliters of the total eluate was analyzed by nano-HPLC
chromatography on a PepMap C18 reverse-phase column (Applied
Biosystems, USA) with a gradient of acetonitrile in 0.1% formic acid.The eluate from the column was applied online to a LCQ ion trap mass
spectrometer (Thermo-Electron) equipped with a nanospray source.
Mass spectra were searched against non-redundant human databases
using MASCOT (Matrix Science) based software program.
2.5. Immunoblot analysis
The samples for immunoblot analysis were prepared from non-de-
mented human brains obtained from the Slovak brain bank. The frozen
brain tissues were thawed and homogenized in 10 volumes of ice-cold
extraction buﬀer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA,
1 mMDTT, 0.5% Triton X-100, 1 mMNa3VO4, 20 mMNaF), supple-
mented with protease inhibitor cocktail (Complete without EDTA,
Roche) using the OMNI TH tissue homogenizer (OMNI Interna-
tional). After incubation on ice for 5 min the homogenates were cleared
by centrifugation at 20000 · g for 20 min at 4 C. The supernatants
were collected and the total protein concentration was determined using
the BioRad Protein Assay (BioRad). The supernatants were then mixed
with equal volume of 2· SDS sample loading buﬀer [29] and heated at
95 C for 5 min. Ten micrograms of total protein was separated by elec-
trophoresis in 12% SDS–polyacrylamide gels and then transferred onto
nitrocellulose membrane in 10 mM CAPS (pH 12). After the transfer
the membranes were blocked in 5% non-fat dry milk in TBST
(10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.05% Tween 20) and then
incubated with DC63 hybridoma culture supernatant (diluted 1:1 in
TBST-5% milk) for 1 h at room temperature followed by polyclonal
goat anti-mouse IgG, horseradish peroxidase-conjugated (1:10000,
DAKO, Denmark). The blots were developed with Super Signal West
Pico Chemiluminescent Substrate (Pierce) detected with LAS3000
imaging system (FUJI Photo Film Co., Japan). The band intensities
were quantiﬁed using Advanced Image Data Analyzer (Aida) software
(Raytest, Straubenhardt, Germany).
2.6. Immunohistochemistry
The brain tissue samples were ﬁxed with 4% paraformaldehyde in
0.1 M PBS (pH 7.2) for 2 days at 4 C and then cryoprotected, frozen
and sectioned on cryotome. Free ﬂoating tissue sections (50 lm) were
immunostained using the standard avidin biotin peroxidase method
(ABC Elite, Vector Laboratories, Burlingame, CA). Sections were then
examined with an Olympus BX 51 microscope.3. Results
3.1. Generation of monoclonal antibody DC63 which identiﬁes a
single band in Western blot analysis of human brain extracts
Monoclonal antibodies were prepared from splenocytes of
mice immunized with recombinant I1PP2A. The immunogen
was isolated from bacterial expression of cDNA encoding
I1PP2A and puriﬁed to homogeneity (28–29 kDa). The cDNA
was prepared from human brain tissue by RT PCR. Sequence
analysis of the cDNA indicated it was identical to the human
I1PP2A cDNA listed in GenBank database (Accession No.
NM_006305, ANP32A/I1PP2A). Recombinant I1PP2A pro-
tein, puriﬁed as described in Section 2, was used as a solid
phase in ELISA for the identiﬁcation of positive hybridomas
(data not shown).
Next, we performed Western blot analysis on protein ex-
tracts from human brains, using hybridoma culture superna-
tants of the ELISA-positive clones. This analysis led to the
identiﬁcation of monoclonal antibody DC63. The antibody
recognized on Western blot a single band of 28–29 kDa in pro-
tein extracts prepared from human brains (Fig. 1A, lanes 1–2).3.2. Mass spectrometry identiﬁcation of I1PP2A as the protein
recognized by DC63 in human brain
As Table 1 indicates, I1PP2A belongs to a large family of
highly conserved proteins. It is therefore conceivable that
DC63 antibody could potentially cross-react with other mem-
Fig. 1. Western blot analysis and immunopuriﬁcation of I1PP2A from
human brain extracts using monoclonal antibody DC63. (A) DC63
recognizes a single band of 28–29 kDa in human brain extracts
(samples from two non-demented patients are shown). (B) Immuno-
puriﬁcation of the DC63-reactive material from human brain extract.
Irrelevant monoclonal antibody DC51 and anti-I1PP2A antibody
DC63 were coupled to Tosylactivated Dynabeads and incubated with
non-denatured human brain extract. The material bound to the
antibodies was analyzed in Western blot with DC63 antibody. Lane 1,
human brain extract; lane 2, the eluate from DC51-Dynabeads
contains only light and heavy chain of DC51; lane 3, the eluate from
the DC63-Dynabeads contains single protein species of 28–29 kDa
(arrowhead). A control Western blot of DC63 – Dynabeads complex
which was not incubated with human brain extract (lane 4) shows
bands pertaining to the antibody itself, the light (L) and heavy (H)
immunoglobulin chains and a week, non-speciﬁc band (asterisk)
produced during coupling the antibody to beads.
B. Kovacech et al. / FEBS Letters 581 (2007) 617–622 619bers of this multi-protein family. To rule out this possibility we
used mass spectrometry to analyze the immunoreactive mate-
rial recognized by the antibody in human brain extract. In or-
der to isolate suﬃcient quantities of target protein for this
analysis we coupled puriﬁed DC63 antibody to Tosylactivated
Dynabeads M280 (Dynal) and used this material to immuno-
purify protein from non-denatured human brain extracts.
The proteins eluted from the DC63-Dynabeads were separated
by SDS–polyacrylamide gel electrophoresis and analyzed by
Western blotting (Fig. 1B). Comparison of the eluates from
the DC63-coupled Dynabeads incubated and non-incubated
with the brain extract shows that the antibody immunopuriﬁed
a single protein species of 28–29 kDa only from brain extract
but not from mock immunopuriﬁcation (Fig. 1B, lanes 3 and
4). The protein immunopuriﬁed from non-denatured brain ex-
tract appears identical to that recognized by DC63 in dena-Table 1
Homology between I1PP2A (249 aa) and other members of the Anp32
family of nuclear acidic proteins
Family member Length (aa) Homology (%)
ANP32B1 251 70
ANP32B2 195 75
ANP32C 234 85
ANP32D 131 89
ANP32E 268 59
ANP32F 223 46
ANP32G 218 71
ANP32H 173 36
The homology table was created with ClustalW [31] WWW Service at
the European Bioinformatics Institute (http://www.ebi.ac.uk/clustalw)
using the amino acid substitution matrix Blosum30.tured human brain extract analyzed in Western blotting
(Fig. 1B, lane 1). An immunopuriﬁcation with irrelevant
monoclonal antibody DC51 coupled to Dynabeads and incu-
bated with the human brain extract did not yield any protein
(Fig. 1B, lane 2).
The 28–29 kDa band containing DC63-immunopuriﬁed pro-
tein was cut out and analysed by LC-MS/MS (see Section 2 for
details).
The analysis detected 27 ions representing 19 peptides iden-
tiﬁed as the portions of I1PP2A, generating a highly signiﬁcant
score of 902 (Table 2). These peptides represent approximately
35% of I1PP2A amino acid sequence. Seven peptides of them
are exclusively present in I1PP2A and not in other members
of the Anp32 family: KLENLK, NRTPSDVK, ELVLDNSR,
KREPEDEGEDDD, CPNLTHLNLSGNK, TPSDVKELV-
LDNSR, NRTPSDVKELVLDNSR. Their presence unequiv-
ocally determined the identity of the protein immunopuriﬁed
by the immobilized DC63 antibody as I1PP2A. The remaining
12 peptides of I1PP2A represent highly conserved sequences,
shared by the members of the Anp32 protein family. Impor-
tantly, no peptides speciﬁc for Anp32 family members other
than I1PP2A were identiﬁed by mass spectrometry.
Therefore we can conclude that the mass spectrometry anal-
ysis by LC-MS/MS unequivocally showed that the DC63
immunoaﬃnity puriﬁed protein (recognition target of DC63)
from non-denatured human brain tissues is I1PP2A. Further-
more, no other Anp32 family member was found to be present
in the immunopuriﬁed protein band. Thus, the antibody is
monospeciﬁc for I1PP2A in adult human brain.3.3. Distribution of I1PP2A in the human brain
Having conﬁrmed the speciﬁcity of the DC63 monoclonal
antibody for its protein target I1PP2A we next sought to use
this reagent to examine the relative distribution of the phos-
phatase inhibitor in various human brain areas. Total protein
extracts were prepared from frozen samples of six human brain
areas of non-demented individuals (see Section 2): hippocam-
pus, temporal cortex, parietal cortex, subcortical nuclei, brain
stem and cerebellum. Western blot analysis was then per-
formed using the DC63 antibody and, as a control a commer-
cially obtained antibody speciﬁc for neuron-speciﬁc enolase.
The results from a representative experiment, as well as a table
depicting the quantitation of results from a series of experi-
ments are shown in Fig. 2. These data indicate that the expres-
sion levels of I1PP2A are similar in all brain regions, with the
exception of the cerebellum, in which expression levels are
approximately twice those observed elsewhere in the brain.
The immunohistochemical study conﬁrmed distribution of
I1PP2A in majority of neuronal cells in diﬀerent brain areas
including isocortex, subcortical areas, hippocampus and brain
stem (Fig. 3). Observation at higher magniﬁcation (1000·)
revealed the most intense DC63 immunoreactivity in the neu-
ronal nuclei. Strong immunostaining was seen in white matter,
which indicated, that I1PP2A protein is expressed also in glial
cells.4. Discussion
Recent studies suggest that alterations in the phosphoryla-
tion status of tau in neurons can be caused either by excessive
Table 2
Mascot score table for peptides derived from the I1PP2A/ANP32A protein
Observed Mr(exp) Mr(calc) Delta Miss Score Rank Peptide
616.52 615.51 615.36 0.15 0 27 2 LENLK
636.40 635.39 635.33 0.06 0 30 1 ENVFK
744.50 743.49 743.45 0.04 1 42 1 KLENLK
780.61 779.60 779.47 0.14 0 27 1 IHLELR
846.50 845.49 845.42 0.07 0 33 2 LELSDNR
916.55 915.54 915.48 0.06 1 40 1 NRTPSDVK
936.63 935.62 935.57 0.06 1 31 1 RIHLELR
945.51 944.50 944.49 0.01 0 53 1 ELVLDNSR
947.57 946.56 944.49 2.07 0 (38) 1 ELVLDNSR
974.47 973.46 973.52 0.06 1 (35) 1 KLELSDNR
488.75 975.48 973.52 1.96 1 43 1 KLELSDNR
1015.39 1014.38 1014.56 0.18 0 42 1 DLSTIEPLK
508.69 1015.37 1014.56 0.81 0 (32) 1 DLSTIEPLK
551.52 1101.03 1100.61 0.42 0 52 1 VSGGLEVLAEK
572.72 1143.42 1142.65 0.77 1 35 2 DLSTIEPLKK
608.56 1215.11 1214.70 0.41 2 57 1 LKKLELSDNR
1256.49 1255.48 1255.74 0.26 1 (43) 1 IKDLSTIEPLK
629.81 1257.61 1255.74 1.87 1 67 1 IKDLSTIEPLK
693.72 1385.42 1383.83 1.59 2 64 1 IKDLSTIEPLKK
1433.43 1432.42 1432.56 0.14 2 79 1 KREPEDEGEDDD
717.48 1432.94 1432.56 0.38 2 (44) 1 KREPEDEGEDDD
734.45 1466.89 1466.74 0.15 0 64 1 CPNLTHLNLSGNK + carbamidomethyl (C)
787.59 1573.16 1571.82 1.35 1 74 1 TPSDVKELVLDNSR
525.45 1573.32 1571.82 1.51 1 (34) 1 TPSDVKELVLDNSR
922.39 1842.76 1841.96 0.80 2 65 1 NRTPSDVKELVLDNSR
615.32 1842.92 1841.96 0.96 2 (19) 6 NRTPSDVKELVLDNSR
615.42 1843.22 1841.96 1.26 2 (40) 2 NRTPSDVKELVLDNSR
Mass: 28568, total score: 902, peptides matched: 27.
Individual ions scores >44 indicate identity or extensive homology (P < 0.05).
Observed – experimental m/z value.
Mr(exp) – experimental m/z value transformed to a relative molecular mass.
Mr(calc) – calculated relative molecular mass of the matched peptide.
Delta – diﬀerence (error) between the experimental and calculated masses.
Miss – number of missed enzyme cleavage sites.
Score – ions score. If there are duplicate matches to the same peptide, then the lower scoring matches are shown in brackets.
Rank – rank of the ions match, (1–10, where 1 is the best match).
Fig. 2. I1PP2A is present in all human brain regions. (A) Western blot analysis of the distribution of I1PP2A in six areas of the human brain. The
blot was ﬁrst probed with the DC63 antibody, then stripped and re-probed with the MIG-N3 antibody against neuron-speciﬁc enolase (NSE)
(Abcam). (B) Relative abundance of the I1PP2A in the six brain areas. H, hippocampus; TC, temporal cortex; BS, brain stem; PC, parietal cortex;
SN, subcortical nuclei; C, cerebellum.
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Fig. 3. The distribution pattern of I1PP2A in the human brain. Monoclonal antibody DC63 recognized I1PP2A in diﬀerent brain areas including
enthorinal cortex (A, B) and hippocampus (C, D). In the cortical area DC63 recognized also glial cells in the white matter (B). Higher magniﬁcation
(1000·) showed that the antibody decorates granular structures in the nuclei of pyramidal cells (D). Scale bars represent 100 lm in A–C and 20 lm
in D.
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of tau phosphatases [30]. In vitro studies of the regulation of
tau protein phosphatase PP2A showed that inhibitor 1
(I1PP2A) is a potent regulator of the phosphatase [14,15]. This
ﬁnding was extended by in vivo studies suggesting that I1PP2A
is dysregulated in AD [16,17]. The inhibitor I1PP2A is a mem-
ber of the Anp32 family consisting of 32 evolutionarily con-
served proteins. In humans, the closely related family of
acidic leucine rich nuclear phosphoproteins consists of 9 highly
similar members (ANP32A/I1PP2A, ANP32B1, B2, C, D, E,
F, G, H) [26]. The main tools used for determination of subcel-
lular localization and brain expression levels of I1PP2A are
polyclonal and monoclonal antibodies. Despite the high con-
servation amongst the family members (up to 89% similarity)
in no instance has the binding target – the protein(s) they rec-
ognize in brain – been conﬁrmed to be I1PP2A. In the present
study we have described a novel protein molecular probe –
DC63 – which speciﬁcally recognizes I1PP2A in human brain
extracts. DC63 immunoaﬃnity chromatography of non-dena-
tured human brain extracts yielded a single puriﬁed protein of
28–29 kDa. Although the DC63 antibody was produced using
recombinant I1PP2A and recognized in human brain extracts a
protein of the same molecular size, we still could not assign the
inhibitor 1 as the recognition target of DC63 because it be-
longs to the large ANP32 family of highly conserved proteins.
Therefore the aﬃnity-puriﬁed protein was subjected to tandem
mass spectrometry analysis in LC-MS/MS. The data showed
that recognition target of DC63 monoclonal antibody in
human brain is indeed the inhibitor 1 of protein phosphatase
2A recognized as a unimolecular species. Quantitative analysis
of individual human brain regions with DC63 revealed for the
ﬁrst time that I1PP2A is evenly distributed in all regions of the
human brain, except the cerebellum. The known higher levels
of the inhibitor in cerebellum were conﬁrmed by our study.
The speciﬁcity and molecularly conﬁrmed recognition target
of DC63 allowed us unequivocally assign the subcellular local-
ization of I1PP2A to the nuclei of neurons and glial cells.
The present study describes a novel I1PP2A-selective molec-
ular probe – DC63 – that may be used for in vitro and in vivo
qualitative and quantitative studies of physiological and path-
ological pathways involving I1PP2A.
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